

ReCLAIM

Dry Age-Related Macular Degeneration



An open-label, phase 1 study to evaluate the safety and tolerability of 24 weeks' treatment with daily subcutaneous injections of elamipretide in patients with intermediate age-related macular degeneration.

UP
TO **8M**

AMERICANS AGED 40+
HAVE INTERMEDIATE AMD

The trial will assess
approximately 40 patients

AGES 55+



TRIAL BEGAN
Q3 2016

TRIAL SITES



1 trial center

Durham, North Carolina
SCOTT COUSINS, MD

ENDPOINTS

PRIMARY

Safety and tolerability

SECONDARY

Changes from baseline
in physical/ophthalmic examinations